The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refrac tory multiple myeloma. The immunomodulatory agent pomalidomide plus dexa methasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor.
D espite the widespread use of immunomodulatory agents and proteasome in hibitors, relapsed or refractory multiple myeloma is common, in part because of clonal heterogeneity and genomic complexity. 1 The prog nosis is poor once the disease becomes refrac tory to proteasome inhibitors and immunomodu latory drugs; indeed, a median overall survival of 9 months was reported after treatment failure with bortezomib and lenalidomide or thalidomide. 2 Therapies that combine agents with different mechanisms of action have improved outcomes in patients with relapsed or refractory multiple myeloma. The triplet regimen of elotuzumab plus lenalidomide and dexamethasone is indicated for patients with multiple myeloma who have received at least one previous therapy. 3, 4 Elotuzumab is a humanized immunoglobulin G1 immunostimu latory monoclonal antibody that binds signaling lymphocytic activation molecule F7 (SLAMF7), a glycoprotein that is highly expressed on the sur face of myeloma cells, natural killer cells, and some immune cells, but not on other normal tissues. 5, 6 The mechanism of action of elotuzu mab includes natural killer cell-mediated anti bodydependent cellular cytotoxicity on SLAMF7 expressing myeloma cells and direct activation of natural killer cells. 59 In addition, elotuzumab may facilitate macrophagemediated killing of myeloma cells. 10 In the phase 3 ELOQUENT2 trial, elotuzumab plus lenalidomide and dexa methasone was associated with a risk of pro gression or death that was 30% lower than that with lenalidomide and dexamethasone, without markedly increased toxic effects 11 ; both efficacy and safety findings were sustained over an ex tended 5year followup period. 12 Pomalidomide, an immunomodulatory agent, has structural and mechanistic properties that are similar to those of lenalidomide, but it may also elicit distinct biologic effects. 13, 14 Pomalido mide is approved in combination with dexameth asone for patients with multiple myeloma who have received at least two previous therapies, in cluding lenalidomide and a proteasome inhibitor, and whose disease is refractory to their last therapy.
15, 16 In pivotal phase 2 and phase 3 trials, overall response rates of 33% and 31%, respec tively, and a median progressionfree survival of approximately 4 months were observed in patients who had previously received lenalidomide and bortezomib. 17, 18 In the United States, pomalido mide in combination with daratumumab and dexamethasone is also approved for use in pa tients who have received previous treatment with lenalidomide and a proteasome inhibitor 19 ; a noncomparative trial involving 103 patients who received this combination regimen showed an overall response rate of 60% and median pro gressionfree survival of 8.8 months. 20 The combination of elotuzumab and pomalid omide may have synergistic clinical effects in patients with multiple myeloma that relapsed after treatment with lenalidomide or is refractory to lenalidomide. Because immunomodulatory drugs act through several mechanisms, 21 ,22 poma lidomide may enhance the immune cell-medi ated killing of myeloma cells by elotuzumab. In addition to the potential for increased efficacy with elotuzumab and pomalidomide, the favor able, wellcharacterized safety profile of elotuzu mab plus lenalidomide and dexamethasone sug gests that the combination of elotuzumab and pomalidomide is unlikely to result in markedly increased toxic effects. 11, 12, 23 Indeed, initial safe ty results from a noncomparative phase 2 study of elotuzumab plus pomalidomide and dexameth asone are consistent with the predicted level of toxic effects of this regimen. 24 Here, we report the results from ELOQUENT3, a randomized trial in which we assessed the ef ficacy and safety of the monoclonal antibody elotuzumab plus pomalidomide and dexametha sone as compared with pomalidomide and dexa methasone alone in patients with refractory or relapsed and refractory multiple myeloma who had previously received treatment with lenalido mide and a proteasome inhibitor.
Me thods

Study Design and Oversight
This multicenter, randomized, openlabel, phase 2 trial was designed by the sponsors (BristolMyers Squibb and AbbVie Biotherapeutics) and investi gators. The trial was conducted in accordance with International Conference on Harmonisa tion Good Clinical Practice guidelines. The pro tocol, which was approved by the institutional review board or independent ethics committee at each participating trial center before the start of the trial, is available with the full text of this article at NEJM.org. All the patients provided written informed consent. The investigators col lected the data, which were maintained by the sponsors. The manuscript was prepared with A Quick Take is available at NEJM.org assistance from professional medical writers who were funded by BristolMyers Squibb. The authors contributed to the development of the manu script, approved the final version, and vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol.
Patients
Eligible patients were 18 years of age or older and had measurable multiple myeloma and an Eastern Cooperative Oncology Group performance status score of 0 to 2 (on a 5point scale, with higher numbers indicating greater disability). Patients had received two or more previous lines of therapy, including at least two consecutive cy cles of lenalidomide and a proteasome inhibitor alone or in combination. Eligible patients had multiple myeloma that was refractory (disease progressed while the patient was receiving treat ment or within 60 days after treatment discon tinuation) or relapsed and refractory (disease progressed within 6 months after treatment dis continuation after the patient had at least a par tial response) to lenalidomide and a proteasome inhibitor. In addition, all patients had multiple myeloma that was refractory to their last therapy. Key exclusion criteria were previous treatment with pomalidomide, active plasmacell leukemia, and a creatinine clearance of less than 45 ml per minute. Further details regarding the inclusion and exclusion criteria can be found in the Sup plementary Appendix, available at NEJM.org.
Randomization and Treatment
Patients were randomly assigned, in Prophylaxis against thromboembolism was required for all patients according to institutional guidelines or at the discretion of the investigator. Patients in the elotuzumab group received the following medications 45 to 90 minutes before each dose of elotuzumab: diphenhydramine at a dose of 25 to 50 mg or equivalent, ranitidine at a dose of 50 mg or equivalent, and acetaminophen at a dose of 650 to 1000 mg.
End Points and Assessments
The primary end point was investigatorassessed progressionfree survival, which was defined as the time from randomization to the first occur rence of disease progression (not including clini cal deterioration) or death from any cause, which ever occurred first. The analysis was based on the intentiontotreat population, which included all patients who underwent randomization. Sec ondary end points were the overall response rate (partial response or better), as assessed by the investigators, and overall survival. Exploratory end points included the time to response, the dura tion of response, and safety (end points are de scribed in detail in the Supplementary Appendix). An independent review committee whose mem bers were unaware of the treatment assignments also assessed progressionfree survival and over all response rate to confirm the results of the investigator assessment. Response assessments were based on International Myeloma Working Group consensus criteria, 2527 except for assess ment of minor (minimal) response, which was derived from European Society for Blood and Marrow Transplantation criteria (see the Supple mentary Appendix).
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Statistical Analysis
For the final analysis of progressionfree sur vival, we calculated that 114 patients would have to undergo randomization and 71 events (disease progression or death) would have to occur to pro vide the trial with 85% power to detect a hazard ratio for disease progression or death of 0.57 in the elotuzumab group as compared with the con trol group, using a logrank test with a twosided experimentwise alpha of 0.2 (additional details are provided in the Supplementary Appendix). Progressionfree survival and its associated medi an were estimated by the Kaplan-Meier method. Progressionfree survival was compared with the use of a twosided stratified logrank test, and the hazard ratio of the elotuzumab group to the control group was estimated with a stratified Cox proportionalhazards model, with treatment as the single covariate. Subgroup analyses of progressionfree survival were also performed. The overall response rate in the two groups (final analysis) was compared with the use of a Cochran-Mantel-Haenszel test and its corre sponding estimate of treatment odds ratio. Pre liminary overall survival was estimated by the Kaplan-Meier method; a preliminary hazard ra tio was estimated with the use of a stratified Cox proportionalhazards model, with treatment as the single covariate.
R esult s
Patients and Treatment
Patients were enrolled from March 2016 through April 2017 at 43 sites in Europe, North America, Japan, and Australia. Overall, 60 patients were randomly assigned to the elotuzumab group and 57 to the control group; all but 2 patients (both in the control group) received their assigned treat ment (Fig. S2 in the Supplementary Appendix). The characteristics of the two treatment groups were generally well balanced at baseline ( Table 1) . The median number of previous lines of therapy was 3 (range, 2 to 8) in both groups. In all, 68% of the patients in the elotuzumab group and 72% in the control group had multiple myeloma that was refractory to both lenalidomide and a proteasome inhibitor.
At the time of the database lock (February 2018), after a minimum followup period of 9.1 months, 40% of treated patients in the elotuz umab group, as compared with 20% in the con trol group, were continuing to receive the as signed treatment (Fig. S2 in . ‡ Fluorescence in situ hybridization was performed at a central laboratory to detect cytogenetic mutations. Positivity for each cytogenetic mutation was based on the identification of at least 1 abnormal cell out of a minimum of 100 cells examined, with the exception of del17p, which required at least 60% abnormal cells. Positivity for 1q21 required at least three copies of 1q21 in 1 cell. § Only previous therapies of interest are reported. As a result of a protocol deviation, one patient in the elotuzumab group did not receive previous treatment with lenalidomide. ¶ A total of five patients (one in the elotuzumab group and four in the control group) had disease with an unknown status with respect to either lenalidomide or a proteasome inhibitor (protocol deviations).
Table 1. (Continued.)
T h e ne w e ngl a nd jou r na l o f m e dicine of the trial treatment was disease progression (43% of the treated patients in the elotuzumab group and 56% of the treated patients in the control group). The median number of treatment cycles was 9 (interquartile range, 4 to 13) in the elotuzumab group and 5 (interquartile range, 3 to 10) in the control group.
A total of 55% of the patients in the elotuzu mab group and 53% in the control group received at least 90% of the planned doses of pomalido mide. Pomalidomide dose reductions occurred in 20% of the patients in each treatment group. Elotuzumab dose reductions were not permitted, but dose delays occurred in 33% of the patients in the elotuzumab group.
Efficacy
The median investigatorassessed progressionfree survival was 10.3 months (95% confidence inter val [CI], 5.6 to not reached) in the elotuzumab group and 4.7 months (95% CI, 2.8 to 7.2) in the control group. The hazard ratio for disease pro gression or death was 0.54 (95% CI, 0.34 to 0.86; P = 0.008), which represents a risk of progression or death that was 46% lower in the elotuzumab group than in the control group (Fig. 1A) . The corresponding Kaplan-Meier curves of progres sionfree survival showed early separation that was sustained over time. Thus, the progression free survival benefit of elotuzumab plus pomalido mide and dexamethasone was significant not only at the prespecified alpha level of 0.2 that the trial was powered to detect but also at the more stringent significance level of 0.05.
The progressionfree survival benefit of elotuz umab was consistently observed across key pa tient subgroups that were defined according to baseline characteristics, including patients whose disease was refractory to both lenalidomide and a proteasome inhibitor, patients who were assessed as having highrisk disease on the basis of Inter national Myeloma Working Group criteria, and patients with at least one cytogenetic abnormality (chromosome 17p deletion, t[4;14] transloca tion, or t[14;16] translocation) or at least one of the aforementioned cytogenetic abnormalities or a high lactate dehydrogenase level (Fig. 1B, and  Fig. S3 in the Supplementary Appendix). The benefit of elotuzumab was also seen in patients who had received at least four previous lines of therapy; the median progressionfree survival among these patients was 10.3 months (95% CI, 3.7 to not reached) in the elotuzumab group and 4.3 months (95% CI, 1.9 to 9.3) in the control group (hazard ratio, 0.51; 95% CI, 0.24 to 1.08).
The median progressionfree survival in the overall population as assessed by the indepen dent review committee was 10.3 months (95% CI, 6.5 to not reached) in the elotuzumab group and 4.7 months (95% CI, 2.8 to 7.6) in the con trol group; the hazard ratio for progressionfree survival was 0.51 (95% CI, 0.32 to 0.82) in favor of the elotuzumab group. Concordance between investigator assessments and independent review committee assessments of progressionfree sur vival was 85%.
According to investigator assessments, 20% of the patients in the elotuzumab group and 9% in the control group had a very good partial re sponse or better. The overall response rate was higher in the elotuzumab group (53%; 95% CI, 40 to 66) than in the control group (26%; 95% CI, 16 to 40), with an odds ratio of 3.25 (95% CI, 1.49 to 7.11) ( Table 2 ). The overall response rate as assessed by the independent review commit tee was 58% (95% CI, 45 to 71) in the elotuzu mab group as compared with 25% (95% CI, 14 to 38) in the control group, with an odds ratio of 4.62 (95% CI, 2.05 to 10.43). Concordance be tween investigator assessments and independent review committee assessments of overall response rate was 91%. 
Months since Randomization
Hazard ratio for disease progression or death, 0.54 (95% CI, 0.34-0.86) P=0.008 T h e ne w e ngl a nd jou r na l o f m e dicine Overall survival data were immature at the time of the analysis; however, a trend favoring the elotuzumab group was observed (hazard ratio for death, 0.62; 95% CI, 0.30 to 1.28) (Fig. 2 ). There were 13 deaths (22%) in the elotuz umab group and 18 deaths (32%) in the control group; these 31 deaths represented 40% of the 78 deaths that would need to occur for the final analysis of over all survival. Disease progression was the main cause of death in both groups (13% of the treated patients in the elotuzumab group and 25% of the treated patients in the control group).
No. at Risk
Elotuzumab group
The median time to response was similar in the two groups: 2.0 months in the elotuzumab group and 1.9 months in the control group. The median duration of response was not reached (95% CI, 8.3 to not reached) in the elotuzumab group and was 8.3 months (95% CI, 4.6 to not reached) in the control group (Fig. S4 in the Supplementary Appendix).
Safety
Adverse events of any cause that were reported in at least 10% of the patients in either treatment group and adverse events of special interest are shown in Table 3 . Grade 3 or 4 adverse events were reported in 57% of the patients in the elo tuzumab group and in 60% in the control group; the most common events were neutropenia (13% in the elotuzumab group vs. 27% in the control group), anemia (10% vs. 20%), and hyperglycemia (8% vs. 7%). Infections of any grade were re ported in 65% of the patients in each of the two groups, with grade 3 or 4 infections occurring in 13% of the patients in the elotuzumab group and in 22% in the control group. When we ad justed for exposure to the trial medication, the rate of infection was 182 events per 100 patient years in the elotuzumab group and 230 events per 100 patientyears in the control group (Table  S1 in the Supplementary Appendix).
The incidence of serious adverse events was 53% in the elotuzumab group and 55% in the control group. One patient in the control group had a second primary cancer (grade 4 invasive breast carcinoma) that resulted in discontinua tion of treatment. The most common treatment related adverse events were neutropenia (18% in the elotuzumab group vs. 20% in the control group), hyperglycemia (18% vs. 11%), and ane mia (10% vs. 15%) ( Table S2 in the Supplemen tary Appendix).
Adverse events that led to discontinuation of treatment occurred in 18% of the patients in the elotuzumab group and in 24% of the patients in the control group; infections led to discontinua tion in 7% of the patients in the elotuzumab group and in 5% in the control group. No deaths in either group were considered by the investiga tors to be due to the trial medication.
At the time of the database lock, a total of 816 infusions of elotuzumab had been adminis Very good partial response 7 (12) 4 (7) Combined response † 12 (20) 5 (9) Partial response 20 (33) 10 (18) Minor response 4 (7) 8 (14) Stable disease 13 (22) 16 (28) Progressive disease 7 (12) 9 (16) Response could not be evaluated or was not reported 4 (7) 9 (16) * Included are all patients who underwent randomization. Definitions of response and disease progression were modified from International Myeloma Working Group criteria, 25, 26 except for the definition of minor (minimal) response, which was derived from European Society for Blood and Marrow Transplantation criteria 28 (see the Supplementary Appendix). † Combined response was defined as very good partial response or better. Table 2 . Investigator-Assessed Treatment Response.* tered; three infusion reactions had occurred (deafness, chest discomfort, and an unspecified infusionrelated reaction occurred in one patient each). All the infusion reactions were grade 1 or 2, and all resolved.
Discussion
The findings from this randomized trial showed that the addition of the monoclonal antibody elotuzumab to pomalidomide and dexamethasone resulted in a significant improvement over poma lidomide and dexamethasone alone in treatment outcomes of relapsed or refractory multiple my eloma. Specifically, the Kaplan-Meier curves for progressionfree survival showed early separation that was sustained over time, with a risk of pro gression or death that was 46% lower in the elotuzumab group than in the control group. In addition, the odds ratio for the overall response rate showed that patients in the elotuzumab group were 3.25 times as likely to have a response to treatment as patients in the control group. These clinical data confirm the findings of pre clinical studies in mice, which showed that elotuz umab, pomalidomide, and dexamethasone syn ergize to kill myeloma cells (Fig. S5 in the Supplementary Appendix).
Therapies approved for patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor include pomalidomide and dexamethasone, daratumumab monotherapy, and daratumumab plus pomalidomide and dexa methasone. 16, 19 In the phase 3 trial (MM003) of pomalidomide and dexamethasone, the median progressionfree survival was 4.0 months and the overall response rate was 31%, 18 findings that are consistent with those reported in the control group in our trial (4.7 months and 26%, respec tively). In the current trial, the median progres sionfree survival with elotuzumab plus pomalido mide and dexamethasone was 10.3 months and the overall response rate was 53%, which shows the superiority of that treatment over pomalido mide and dexamethasone alone. In a noncom parative phase 1b trial that evaluated daratumu mab plus pomalidomide and dexamethasone in 103 patients who had received a median of four previous lines of therapy, the median progres sionfree survival was 8.8 months and the overall response rate was 60%. 20 In our trial, the treat ment effect of elotuzumab was observed across several subgroups, including patients who had received at least four previous lines of therapy, with a median progressionfree survival of 10.3 months as compared with 4.3 months in the con trol group, and a hazard ratio for disease progres sion or death of 0.51. The benefit of combining a * Listed are adverse events that occurred on or after the first dose until 60 days after the last dose. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Only adverse events that were reported in at least 10% of patients in either treatment group are shown, except for adverse events of special interest, for which no cutoff in percentage was applied. Adverse events that resulted in death (grade 5 events) occurred in five patients (8%) in the elotuzumab group and in eight patients (15%) in the control group. In the elotuzumab group, three patients died from infection and one each from cardiac failure and general physical health deterioration. In the control group, one patient died from infection, one from multiorgan failure and infection, one from myocardial infarction, one from plasma-cell myeloma, and four from malignant neoplasm progression. † This term includes malignant, benign, and unspecified neoplasms. Grade 5 neoplasms were reported in five patients (9%) in the control group and in no patients in the elotuzumab group. third agent with pomalidomide and dexametha sone has also been shown in a randomized, phase 2 trial of pomalidomide and dexametha sone with or without cyclophosphamide, in which the overall response rate was 1.7 times as high in the cyclophosphamide group as in the control group. 29 In the current trial, the overall response rate in the elotuzumab group was twice as high as the rate in the control group. Collectively, these data suggest that elotuzumab plus poma lidomide and dexamethasone is an effective combination and represents an alternative treat ment option to other pomalidomide and dexa methasone-based regimens. However, caution is warranted when comparing results across trials.
Elotuzumab plus pomalidomide and dexa methasone was associated with a rate of grade 3 or 4 adverse events (57%) that was similar to that observed with pomalidomide and dexa methasone alone (60%); no new safety signals were identified beyond the findings reported with other elotuzumab and pomalidomide regi mens. 11, 12, 17, 18, 23 Despite a longer duration of ex posure to the trial medication in the elotuzumab group than in the control group, the incidence of adverse events that led to discontinuation of treatment was lower in the elotuzumab group than in the control group. When we adjusted for exposure to the trial medication, infections were less common in the elotuzumab group than in the control group. The occurrence of infusion reactions was minimal, a finding that is consis tent with that in other elotuzumab trials. 11, 23 Treatment with pomalidomide and dexametha sone has been reported to be associated with neutropenia, a risk that may be increased with the addition of daratumumab. 20 In contrast, the addition of elotuzumab did not result in a higher rate of treatmentrelated neutropenia than that without elotuzumab (18% in the elotuzumab group and 20% in the control group). Neutrope nia and anemia of any cause were less common in the elotuzumab group than in the control group, even though the dose intensity of poma lidomide in the two groups was balanced. In addition, the similarity of the dose intensity of pomalidomide in the two groups suggests that elotuzumab does not affect pomalidomide dos ing. Overall, these results support the initial findings of an ongoing noncomparative, phase 2 trial, 24 which suggests that elotuzumab plus pomalidomide and dexamethasone has a safety profile that is similar to that of elotuzumab plus lenalidomide and dexamethasone and that elo tuzumab is not associated with a higher rate of toxic effects than pomalidomide and dexametha sone alone. 17, 18 This trial, which was specifically designed to detect a large treatment effect in a relatively small sample, showed a significant benefit of elotuzumab plus pomalidomide and dexametha sone with respect to the primary end point of progressionfree survival. Furthermore, the pro gressionfree survival results, as assessed by the investigators, were confirmed by blinded, inde pendent central review. Monthly administration of elotuzumab starting in cycle 3 was effective and provided a potentially more convenient dos ing schedule for patients than the approved dos ing schedule of every other week. 3, 4 The results thus far are encouraging, but extended followup is warranted to determine longterm efficacy and safety outcomes, including the final analysis of overall survival. This trial showed the therapeu tic potential of a second elotuzumabbased com bination therapy for relapsed or refractory multi ple myeloma. Elotuzumab plus lenalidomide and dexamethasone is approved for multiple myelo ma after treatment with at least one previous therapy 3, 4 on the basis of the results of the phase 3 ELOQUENT2 trial, in which most patients had not received lenalidomide. 11 In contrast, patients in the current trial had multiple myeloma that was refractory or relapsed and refractory to lena lidomide.
In conclusion, among patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor, the combination of elotuzumab plus pomalidomide and dexamethasone resulted in significantly longer progressionfree survival and a higher overall response rate than pomalidomide and dexamethasone alone. The previously report ed safety profile of this regimen was confirmed and was similar to that of pomalidomide and dexamethasone alone.
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